https://orcid.org/0000-0002-4506-0061
References
- Miesbach W, O’Mahony B, Key NS, Makris M. How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia. 2019;25(4):545–557. doi:10.1111/hae.13769
- Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357–2365. doi:10.1056/NEJMoa1108046
- Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994–2004. doi:10.1056/NEJMoa1407309
- George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215–2227. doi:10.1056/NEJMoa1708538
- Miesbach W, Meijer K, Coppens M, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 2018;131(9):1022–1031. doi:10.1182/blood-2017-09-804419
- Rangarajan S, Walsh L, Lester W, et al. Factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377(26):2519–2530. doi:10.1056/NEJMoa1708483
- Leebeek F, Meijer K, Coppens M, et al. Stable expression of FIX and maintained reductions in bleeding and factor IX consumption following AMT-060 gene therapy with up to 3.5 years of follow up in adults. Res Pract Thromb Haemost. 2019;3(S1):1–228.
- Miesbach W, Sawyer E. Practical implications of factor IX gene transfer for individuals with hemophilia B: a clinical perspective. Hum Gene Ther Clin Dev. 2018;29(2):80–89. doi:10.1089/humc.2017.253
- Iorio A, Skinner MW, Clearfield E, et al. coreHEM panel. Core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project. Haemophilia. 2018;24(4):e167–e172. doi:10.1111/hae.2018.24.issue-4
- Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. doi:10.1191/1478088706qp063oa